Related Experiment Videos
Long-term lymphocytapheresis therapy in multiple sclerosis. Preliminary observations.
European Neurology
|January 1, 1986
Summary
Long-term lymphocytapheresis (LPH) therapy offers a promising alternative for multiple sclerosis (MS) patients. This treatment reduced relapses and improved symptoms in many participants, suggesting its potential as an immunosuppressive therapy alternative.
Area of Science:
- Immunology
- Neurology
- Therapeutics
Background:
- Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
- Relapsing-remitting MS (RRMS) is characterized by unpredictable bouts of neurological symptoms.
- Current treatments often involve continuous immunosuppressive drug administration.
Purpose of the Study:
- To evaluate the efficacy and tolerability of long-term lymphocytapheresis (LPH) in patients with active relapsing-remitting multiple sclerosis (RRMS).
- To assess the impact of LPH on disease activity, relapse rates, and neurological function.
Main Methods:
- Nine patients with RRMS and frequent relapses received LPH therapy.
- Therapeutic cycles involved 4 LPH sessions over 8 days, repeated every 6-8 weeks for at least 1 year.
- Immunological control was monitored using a myelin-reactive T cell test.
Main Results:
- Long-term LPH therapy was generally well-tolerated, with minor vein-related complications in 2 patients.
- Seven out of nine patients experienced no relapses during LPH therapy.
- Three patients with shorter disease duration showed improvement on the Kurtzke scale, and six patients had reduced relapse rates.
Conclusions:
- Long-term LPH therapy is a viable alternative to continuous immunosuppressive drugs for active MS.
- The treatment appears particularly beneficial for early-stage MS patients.
- LPH demonstrates potential in managing disease activity and improving neurological function in RRMS.